Comment on

• Retinal and Ophthalmic Artery Occlusions Preferred Practice Pattern®.

  Olsen TW, Pulido JS, Folk JC, Hyman L, Flaxel CJ, Adelman RA. Olsen TW, et al. Ophthalmology. 2017 Feb;124(2):P120-P143. doi: 10.1016/j.ophtha.2016.09.024. Epub 2016 Oct 11. Ophthalmology. 2017. PMID: 27742458 Review. No abstract available.
• Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.

  Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Parikh R, et al. Ophthalmology. 2017 Mar;124(3):352-358. doi: 10.1016/j.ophtha.2016.10.036. Epub 2016 Nov 24. Ophthalmology. 2017. PMID: 27890437
• [Guidelines from the DOG, RG and BVA: retinal artery occlusion : November 2016 status].

  Deutsche Ophthalmologische Gesellschaft; Retinologische Gesellschaft e. V.; Berufsverband der Augenärzte Deutschlands e. V.. Deutsche Ophthalmologische Gesellschaft, et al. Ophthalmologe. 2017 Feb;114(2):120-131. doi: 10.1007/s00347-016-0435-1. Ophthalmologe. 2017. PMID: 28160122 German. No abstract available.
• Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.

  Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J; SCORE2 Investigator Group. Scott IU, et al. JAMA. 2017 May 23;317(20):2072-2087. doi: 10.1001/jama.2017.4568. JAMA. 2017. PMID: 28492910 Free PMC article. Clinical Trial.